ZL-1310, an Investigational DLL3-Targeted Antibody-Drug …
Oct 24, 2024 · ZL-1310 is a novel ADC in Zai Lab’s growing, global oncology pipeline that targets Delta-like ligand 3 (DLL3), an antigen that is overexpressed in many neuroendocrine tumors, …
Oct 24, 2024 · • ZL-1310 is a novel ADC that employs the TMALIN® (Tumor Microenvironment Activable LINker-payload) platform and targets DLL3 with an anti-DLL3 monoclonal antibody …
ZL-1310, an Investigational DLL3-Targeted Antibody-Drug …
Oct 24, 2024 · ZL-1310 is being tested in patients with previously treated extensive-stage Small Cell Lung Cancer (ES-SCLC) after at least one prior platinum-based chemotherapy regimen.
Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 …
1 day ago · ZL-1310 is a novel ADC in Zai Lab’s growing, global oncology pipeline that targets Delta-like ligand 3 (DLL3), an antigen that is overexpressed in many neuroendocrine tumors, …
Zai Lab to Present Data from Phase 1 Trial of ZL-1310, Its ...
Nov 26, 2024 · ZL-1310 comprises a humanized anti-DLL3 antibody and a novel camptothecin derivative as its payload. The compound was designed with a novel linker-payload platform …
ZL-1310 Receives Orphan Drug Designation in Small Cell Lung …
1 day ago · ZL-1310, a first-in-class DLL3 antibody-drug conjugate, has been granted orphan drug designation by the FDA for the treatment of patients with small cell lung cancer (SCLC), …
DLL3-Targeted ADC Produces Responses in Previously Treated ES …
Oct 25, 2024 · Developers designed ZL-1310 as a humanized anti-DLL3 monoclonal antibody that links to a topoisomerase 1 inhibitor. The agent’s design may harness the tumor …
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
An Open-label, Multicenter Study of ZL-1310 as a Single Agent and In Combination with Atezolizumab to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects with Small …
Definition of anti-DLL3 ADC ZL-1310 - NCI Drug Dictionary - NCI
anti-DLL3 ADC ZL-1310 An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) delta-like protein 3 (DLL3) and linked to …
Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody …
May 30, 2024 · ZL-1310 is a novel and promising ADC within the Zai Lab global oncology R&D pipeline, targeting the Delta-like ligand 3 (DLL3), a validated therapeutic target in the treatment …
- Some results have been removed